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Background: T-cell responses against highly conserved inﬂuenza antigens have been previously associated with
protection. However, these immune responses are poorly maintained following recovery from inﬂuenza infec-
tion and are not boosted by inactivated inﬂuenza vaccines.We have previously demonstrated the safety and im-
munogenicity of two viral vectored vaccines, modiﬁed vaccinia virus Ankara (MVA) and the chimpanzee
adenovirus ChAdOx1 expressing conserved inﬂuenza virus antigens, nucleoprotein (NP) and matrix protein-1
(M1).Wenow report on the safety and long-term immunogenicity ofmultiple combination regimes of these vac-
cines in young and older adults.
Methods:We conducted a Phase I open-label, randomized, multi-center study in 49 subjects aged 18–46 years
and 24 subjects aged 50 years or over. Following vaccination, adverse events were recorded and the kinetics of
the T cell response determined at multiple time points for up to 18 months.
Findings: Both vaccineswerewell tolerated. A two dose heterologous vaccination regimen signiﬁcantly increased
themagnitude of pre-existing T-cell responses to NP andM1 after both doses in young and older adults. The fold-
increase and peak immune responses after a single MVA-NP + M1 vaccination was signiﬁcantly higher com-
pared to ChAdOx1 NP + M1. In a mixed regression model, T-cell responses over 18 months were signiﬁcantly
higher following the two dose vaccination regimen of MVA/ChAdOx1 NP + M1.
Interpretation: A two dose heterologous vaccination regimen of MVA/ChAdOx1 NP+M1was safe and immuno-
genic in young and older adults, offering a promising vaccination strategy for inducing long-term broadly cross-
reactive protection against inﬂuenza A.
Funding Source:Medical Research Council UK, NIHR BMRC Oxford.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Inﬂuenza A virus (IAV) remains a signiﬁcant global health problem
causing seasonal epidemics and occasional pandemics. Vaccination is
the most cost-effective public health intervention to combat inﬂuenza
(Petrie et al., 2015). Current seasonal inﬂuenza vaccines induce humoral
immune responses to external glycoproteins, hemagglutinin (HA) and
neuraminidase (NA). However, the error-prone nature of inﬂuenza
virus replication leads to the accumulation of drift mutationswithin an-
tigenic sites, allowing escape from serological immunity conferred by
prior infection or vaccination. The requirement tomake advance predic-
tions of which viruses to include in vaccines for the forthcoming inﬂu-
enza season can result in vaccine mismatches (Pebody et al., 2015).
Additionally, responses to seasonal inﬂuenza vaccines are subtype-spe-
ciﬁc, only inducing immune responses to strains included in the vaccine
and offer no heterosubtypic protection against novel subtype
reassortants or emerging viruses like H5N1 or H7N9 avian inﬂuenza.
This is particularly critical in the elderly in whom vaccine efﬁcacy is
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lower, increasing their risk for severe illness (Jefferson et al., 2005; Haq
and McElhaney, 2014; Rivetti et al., 2006).
A protective role for CD4+ and CD8+ T-cells in humans has been
demonstrated in experimental challenge studies (McMichael et al.,
1983b; Wilkinson et al., 2012). More recently, in community cohort
studies, T-cells have been shown to be associated with reduced viral
shedding and limited severity of illness. Sridhar et al. identiﬁed a corre-
lation between the frequency of IFN-γ+/IL-2− CD8+ T-cells and protec-
tion against symptomatic inﬂuenza (Sridhar et al., 2013). Hayward and
colleagues found that higher frequencies of nucleoprotein (NP)-speciﬁc
IFN-γ+ CD3+ T-cells were associated with a lower risk of symptomatic,
PCR-conﬁrmed inﬂuenza infection and viral shedding (Hayward et al.,
2015). As the induction of such cross-protective T-cells following vacci-
nation with current inﬂuenza vaccines is limited (He et al., 2006), alter-
native vaccination approaches to induce T-cell responses against highly
conserved internal inﬂuenza antigens capable of protecting against an-
tigenically distinct viruses with pandemic potential, such as NP or ma-
trix protein 1 (M1), are needed. This would particularly beneﬁt high-
risk populations, such as the elderly, in whom there is a high risk of se-
vere disease.
We have developed viral vectored vaccines, using the replication-
deﬁcient chimpanzee adenovirus ChAdOx1 and the attenuated
orthopoxvirus modiﬁed vaccinia virus Ankara (MVA) expressing NP
and M1 inﬂuenza virus antigens (ChAdOx1 NP + M1 and MVA-NP
+ M1) as one approach to combat this problem. We have previously
demonstrated that a single dose of these viral vector vaccines is safe
and immunogenic (Antrobus et al., 2012; Lillie et al., 2012; Antrobus
et al., 2014b) and in a proof-of-concept experimental inﬂuenza chal-
lenge study, showed that vaccination with MVA-NP + M1 can reduce
the duration of viral shedding (Lillie et al., 2012). However, whether a
vaccination strategy using a heterologous combination of these two
viral vectors is synergistic in inducing higher magnitude, improved
quality and longer durability of T-cell responses, as seen with other an-
tigens, is not known.We conducted this randomized, open-label, Phase
I clinical trial to assess the safety and cellular immunogenicity of prime/
boost vaccination regimes employing MVA-NP+M1 and ChAdOx1 NP
+ M1 in young and older adults.
2. Materials and Methods
2.1. ChAdOx1 NP + M1 and MVA-NP + M1 Vaccines
Both vaccines have been described previously and consist of viral
vectors expressing NP and M1 antigens from inﬂuenza A virus (H3N2,
A/Panama/2007/99) as a single fusion protein (Antrobus et al., 2014b;
Berthoud et al., 2011). MVA-NP + M1 was administered at a dose of
1·5 × 108 plaque forming units (pfu) in 1·15 ml while ChAdOx1 NP
+ M1 was administered at a dose of 2·5 × 1010 viral particles (vp) in
0·22 ml.
2.2. Study Design and Participants
The study was a Phase I open-label, randomized, multi-center study
conducted at the Centre for Clinical Vaccinology and Tropical Medicine,
Oxford, UK, Surrey Clinical Research Centre, University of Surrey, UK
and NIHR Wellcome Trust Clinical Research Facility, Southampton, UK
(Table 1) (CONSORT diagram: Figs. 1 and 2). Healthy adults aged 18–
46 (Groups 1–4) and 50 years or over (Groups 5 and 6) (Table 1)
were eligible to participate in the trial after providing written informed
consent. Full details of eligibility criteria are described in the trial proto-
col provided in the Supplementary material. All volunteers were
healthy adults with negative pre-vaccination tests for HIV antibodies,
hepatitis B surface antigen, hepatitis C antibodies and urine pregnancy
test. Written informed consent was obtained in all cases and the study
was conducted in accordance with the principles of the Declaration of
Helsinki. For Groups 1–4, participants were randomized in variable
block sizes according to vaccine allocation (ChAdOx1 NP + M1 or
MVA-NP + M1 as the ﬁrst vaccine) but not according to interval dura-
tion, which was determined by the preference of the volunteer until
groupswere full. The same randomizationmethodwas used to random-
ize participants to group 5 (ChAdOx1NP+M1only), or 6 (ChAdOx1NP
+M1 followed byMVA-NP+M18weeks later). Thiswas an open label
study with subjects and investigators unblinded to the allocated group
but study personnel conducting the immunology assays were blinded
to group allocation. The clinical trial was approved within the UK by
the regulatory authority (reference 21,584/0311/001-0001) and the
Oxfordshire National Research Ethics Service Committee (OXREC A
13/SC/0004). The trial is registered atwww.clinicaltrials.gov (Identiﬁer:
NCT01818362).
2.3. Study Procedures
All volunteers in Groups 1–4 were vaccinated on the day of enrol-
ment and either 8 or 52 weeks later (CONSORT diagram: Figs. 1 and
2). Volunteers in Group 5 were vaccinated with a single dose of
ChAdOx1 NP + M1 on the day of enrolment and volunteers in Group
6 were vaccinated with ChAdOx1 NP + M1 on the day of enrolment
followed 8 weeks later by MVA-NP + M1. All vaccines were adminis-
tered by an intramuscular (im) injection into the deltoid region of the
arm. Volunteers were reviewed in clinic 24 h after vaccination for po-
tential adverse events (AE) and were provided with a diary card to re-
cord solicited and unsolicited AEs which was reviewed at follow-up
visits. Blood samples for safety and immunogenicity were collected at
each follow-up visit (see Table 1 for timings). Safety events were
assessed as the occurrence of local and systemic reactogenicity signs
and symptoms for 7 days following vaccination procedures. Occur-
rences of serious adverse events were assessed during the whole
study duration and changes from baseline were used for safety labora-
tory measures. Interferon gamma Enzyme-Linked ImmunoSpot assays
(ELISpots) were used as a marker of cell mediated response at baseline
and different time points throughout the trial.
2.4. Statistical Analysis
As a Phase I studywith no predeﬁned hypotheses, formal power cal-
culationswere not performed.With 12 subjects per group (Group 1–4),
it was estimated that there would be 88% power (alpha = 0·05) to ob-
serve a three-fold increase in T-cell response to NP andM1 pre-vaccina-
tion to peak levels post-vaccination, although this was not the primary
endpoint. With 10 per group, we would have 80% power and 68%
power with 8 per group. This informal power calculation was carried
out based on immune responses obtained from our previous trials
with single use of ChAdOx1 NP +M1 and MVA-NP + M1.
All participantswere included in safety analysiswith safety data pre-
sented according to frequency, severity and duration of adverse events.
The primary immunogenicity analysis compared the area under the
curve (AUC) of the T-cell response (IFN-γ SFC/million peripheral
bloodmononuclear cells [PBMCs]) from baseline to week 78 for Groups
1+2 vs 3+4, or from baseline toweek 26 for Group 5 vs 6. For the pri-
mary analysis, a t-test was performed on the intention to treat (ITT)
population. The AUC was calculated using the trapezium method.
Where a response at a time point was missing, we took themean of im-
puted values from twenty imputed datasets (generated using multiple
imputation by chained equations and the predictive mean matching
method). Secondary analyses were performed using a t-test on the
available data only, to compare between pre-speciﬁc groups. No formal
adjustment for multiple signiﬁcance testing was carried out for this
phase I study, but note that all other analyseswere exploratory. Primary,
secondary and post-hoc immunogenicity analyses were carried out
using STATA 14.2: StataCorp. 2015. Stata Statistical Software: Release
14. College Station, TX: StataCorp LP.
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Exploratory immunogenicity data were analyzed using GraphPad
Prism version 5.04 for Windows (GraphPad Software Inc., California,
USA) and non-parametric analyses. To compare ELISpot responses be-
tween selected, matched time-points in a group, a Wilcoxon matched-
pairs signed rank test was used. To compare baseline IFN-γ ELISpot re-
sponses between G1-6 a 1-way ANOVA was used with Kruskal-Wallis
test and Dunn's multiple comparison test. Area under the curve (AUC)
analysis can be used in immunological studies as a tool to estimate over-
all vaccine immunogenicity and durability (Heldens et al., 2002). AUC
values for identical time periods post-vaccination were calculated per
individual for each time point. AUC is presented as AUC/total number
of days post-vaccination when comparing between groups which did
not have match volunteer visits. In order to calculate AUC values
when timepoints weremissing due to absent volunteer visits or ELISpot
Table 1
Trial study design and participant demographics.
Groups Number of
participants
Average age in years
(SD, range)
Sex of participants
(Number/%)
1st vaccination
W0
2nd vaccination
W8
2nd vaccination
W52
Follow up post-immunization
(weeks)
Group 1 12 25·5 (7·4, 21–45) M: 3 (25%)
F: 9 (75%)
ChAdOx1 NP+M1 MVA-NP + M1 – W1, W2, W3, W4,
W8, W9, W10, W11, W26,
W52, W78
Group 2 12 24·8 (6·6, 19–39) M: 5 (41·7%)
F: 7 (58·3%)
ChAdOx1 NP+M1 – MVA-NP + M1 W1, W2, W3, W4,
W8, W26,
W52, W53, W54, W55, W78
Group 3 13a 24·1 (5·3 20–41) M: 5 (38·5%)
F: 8 (61·5%)
MVA-NP + M1 ChAdOx1 NP +M1 – W1, W2, W3, W4,
W8, W9, W10, W11, W26,
W52, W78
Group 4 12 25·6 (7·2, 20–46) M: 3 (25%)
F: 9 (75%)
MVA-NP + M1 – ChAdOx1 NP +M1 W1, W2, W3, W4,
W8, W26,
W52, W53, W54, W55, W78
Group 5 12 61·4 (6·0, 52–72) M: 4 (33·3%)
F: 8 (66·6%)
ChAdOx1 NP+M1 – – W1, W2, W4, W8, W26
Group 6 12 61·6 (8·4, 50–78) M: 5 (41·7%)
F: 7 (58·3%)
ChAdOx1 NP+M1 MVA-NP + M1 – W1,W2, W4, W8, W9, W12W26
a One individual in Group 3 withdrew early after ﬁrst vaccination and was replaced.
Assessed for eligibility (n= 73)
Excluded  (n=24)
¨ Not meeting inclusion criteria (n=7)
¨ Declined to participate (n=15)
¨ Other reasons (n=2)
Analysed  (n = 9-12)
Volunteers lost to follow up were 
not available for analysis of 
immune responses after 2
nd
vaccination
Lost to follow-up (n=0)
Allocated to Group 1 (n=12 )
¨ Received 1
st 
vaccination (n=12)
¨ Received 2
nd
vaccination (n=12)
Randomized (n=49)
Allocated to Group 2 (n=12)
¨ Received 1
st
vaccination (n=12)
¨ Received 2
nd
vaccination (n=8)
Did not receive both vaccines (n=4)
Allocated to Group 3 (n=13)*
¨ Received 1
st
vaccination (n=13)
¨ Received 2
nd
vaccination (n=12)
*One volunteer withdrew and was 
replaced.
Allocated to Group 4 (n=12)
¨ Received 1
st
vaccination (n=12)
¨ Received 2
nd
vaccination (n=9)
Did not receive both vaccines (n=3)
Lost to follow-up (n=4) Lost to follow-up (n=1) Lost to follow-up (n=3)
Analysed  (n=11)
Excluded from analysis due to 
consistent high background in R10 
alone ELISpot wells (n= 1)
Analysed  (n =11)Analysed  (n = 8-12)
Volunteers lost to follow up were not 
available for analysis of immune 
responses after 2
nd
vaccination
Enrolment
Allocation
Follow-up
Analysis
Fig. 1. CONSORT ﬂow diagram of the trial (Groups 1–4). Forty-nine subjects aged 18–46 years were enrolled into four groups (G1–4)with 12 participants in each group. One volunteer in
group 3 withdrew soon after enrolment.
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plate failures, the average of the group at that time-point was used for
analysis. The resulting data sets were analyzed using a non-parametric
two-tailed t-test (Mann-Whitney).
2.5. Ex Vivo IFN-γ ELISpot
Ex vivo interferon-gamma enzyme-linked immunosorbent spot
(IFN-γ ELISpot) assays were performed using fresh PBMC to determine
responses to the NP+M1 vaccine antigen at each timepoint (Antrobus
et al., 2014b). The breadth of the NP+M1-speciﬁc T-cell response was
determined using 8 peptide pools, each pool containing ten 15-20mer
peptides overlapping by 10 amino acids, spanning the complete NP
+ M1 insert.
2.6. Intracellular Cytokine Staining (ICS) and Analysis by Flow Cytometry
Cryopreserved PBMCs were incubated with co-stimulatory antibod-
iesαCD28 andαCD49d and anti-CD107a. Further details of the staining
procedure are outlined in the Supplementary methods and the details of
antibodies used presented in Supplementary Table.1. Brieﬂy,monocytes
(CD14+), B-cells (CD19+) and NK cells (CD56+) were excluded from
analysis. Cells were gated on lymphocytes, singlets, live cells,
CD3+CD14−CD19−, CD4+CD8− or CD8+CD4−, and then assessed for
IFN-γ, IL-2, TNFα secretion and combinations of these cytokines.
3. Results
3.1. Study Population
A total of 49 healthy volunteers aged 18–46 were enrolled and ran-
domized into Groups 1–4 (G1–4) to assess the safety and immunoge-
nicity of a heterologous two dose regimen of ChAdOx1 NP + M1 and
MVA-NP + M1. The average age of the 49 participants who received
at least one vaccination was 25 years (SD: 6·47, range: 19–46 years)
and 16/49 (32%) participantsweremale. One volunteer in G3withdrew
within theﬁrstweek after receiving the ﬁrst MVA-NP+M1 vaccination
and was replaced. Eight further subjects withdrew from the study, 4
after receiving ChAdOx1 NP + M1 in G2 prior to receiving the second
vaccination, 3 in G4 prior to receiving the second vaccination and 1 in
G3 after receiving both vaccinations. In Group 5 and Group 6 (G5 and
G6), 24 healthy volunteers aged 50 or over were enrolled. The average
age of the 24 participants was 61.5 years (SD: 7.14, range: 50–
78 years) and 9/24 (37.5%) were male.
3.2. Vaccine Safety
Administration of ChAdOx1 NP + M1 and MVA-NP + M1 vaccines
was found to be safe andwell-tolerated, in agreementwith our previous
studies.(Antrobus et al., 2014a; Berthoud et al., 2011; Lillie et al., 2012;
Antrobus et al., 2014b; Antrobus et al., 2012) No vaccine-related serious
AEs were observed over the duration of the study. The majority of local
and systemic AEs in all groups were mild to moderate in nature and re-
solved spontaneously within 1–2 days (Table.2). The proportion of par-
ticipants experiencing local and systemic AEs of any severity after
ChAdOx1 NP + M1 or MVA-NP + M1 vaccination was signiﬁcantly
lower (p b 0.01) in individuals ≥ 50 years compared to individuals 18–
46 years.
3.3. Vaccine Immunogenicity in Young Adults
The primary immunogenicity endpoint was the frequency of anti-
gen-speciﬁc T-cells measured by IFN-γ ELISpot (Fig. 3a). There was no
signiﬁcant difference in frequency of pre-existing NP + M1 peptide-
speciﬁc T-cells prior to vaccination between groups and the median re-
sponsewas consistentwith responsesmeasured in our previous clinical
trial (Antrobus et al., 2014b) (Supplementary Fig. 1). The primary anal-
ysis compared ChAdOx1/MVA (combining G1 and G2) and MVA/
ChAdOx1 (G3 andG4 combined) vaccination regimes. Therewas no sig-
niﬁcant difference in the AUC over the entire trial duration of 72 weeks
between ChAdOx1/MVA (G1 + G2) and MVA/ChAdOx1 (G3 + G4) al-
though mixed linear regression of all available responses from all time
points adjusting for time point and baseline values revealed
Enrolment
Allocation
Follow-up
Analysis
Assessed for eligibility (n= 49)
Excluded  (n=25)
¨ Not meeting inclusion criteria (n=16)
¨ Declined to participate (n=2)
¨ Other reasons (n= 7)
Allocated to Group 5 (n=12)
¨ Received 1st vaccination (n=12)
Allocated to Group 6 (n=12)
¨ Received 1
st
prime vaccination (n=12)
¨ Received 2
nd
vaccination (n=12)
Lost to follow-up (n=0 )
Analysed  (n= 12) Analysed  (n= 12)
Lost to follow-up (n=0)
Fig. 2. CONSORT ﬂow diagram of the trial (Groups 5&6). A further twenty-four subjects aged ≥50 years were enrolled into two additional groups, G5 and G6 (12/group).
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signiﬁcantly higher responses (p=0.007)with theMVA/ChAdOx1 reg-
imen than ChadOx1/MVA regimen. Post-hoc analysis of the AUC of im-
mune response showed no signiﬁcant difference between those who
received the second vaccine at week 8 and those who received the sec-
ond vaccine at week 52 (i.e. Group 1 + 3 vs Group 2 + 4).
Regardless of vaccination regimen, T-cell responses measured at the
last time point 18 months after the ﬁrst vaccination were signiﬁcantly
higher than pre-existing baseline levels (G1, p = 0.0049; G2, p =
0.03; G3, p= 0.001; G4, p= 0.04) (Fig. 3a). Similarly, even 52 weeks
after a single vaccination with ChAdOx1 NP + M1 (G2) or MVA-NP
+ M1 (G4), T-cell responses were maintained at levels signiﬁcantly
higher than baseline in both groups (G2: 520 SFU/106 PBMC, p =
0.02; G4: 978·3 SFU/106 PBMC, p= 0.02).
MVA-NP +M1 and ChAdOx1 NP +M1 boosted T-cell responses to
signiﬁcantly higher frequencies either as the ﬁrst or second vaccination
with peak responses typically observed oneweek after vaccination (Fig.
3a). In G1 and G2, ChAdOx1 NP + M1 vaccination was followed by
MVA-NP + M1 8 weeks (W8) or 52 weeks (W52) later, respectively
with peak responses ~5.8-fold higher (2932 SFU/106 PBMC; p =
0.004) in G1 and ~5-fold higher (2683 SFU/106 PBMC; p= 0.02) in G3
compared to responses prior to MVA-NP + M1 vaccination. In G3 and
G4, MVA-NP + M1 was followed by ChAdOx1 NP + M1 at W8 or
W52, respectively. Peak responses following ChAdOx1 NP + M1 boost
vaccination were elevated ~2-fold (1364 SFU/106 PBMC; p= 0.03) in
G3 and ~3-fold (2942 SFU/106 PBMC, p=0.02) compared to responses
prior to ChAdOx1 NP +M1 boost (Fig. 3a).
We compared the fold-change in IFN-γ+ ELISpot response between
peak and pre-vaccination frequencies after ChAdOx1 NP+M1 orMVA-
NP+M1 vaccination (Fig. 4a, b). The fold-increase in pre-existing T-cell
responses after MVA-NP + M1 was signiﬁcantly higher than ChAdOx1
NP + M1, when administered as either the ﬁrst (V1) or the second
(V2) vaccination. In addition to the fold-increase,median peak T-cell re-
sponses after the ﬁrst vaccination with MVA-NP +M1 (2023 SFCs/mil-
lion PBMCs; LQ and UQ: 1349–2750) were signiﬁcantly higher (p =
0.01) than ChAdOx1-NP + M1 (1147 SFCs/million PBMCs; LQ and UQ:
665–1953). No statistically signiﬁcant difference was observed in peak
responses after the second dose.
3.4. Vaccine Immunogenicity in Older Adults
Improving T-cell responses in older adults is a long standing goal for
improved inﬂuenza vaccines and we evaluated the immunogenicity of
the ChAdOx1 NP+M1 vector either as a single (G5) or a two dose reg-
imen with MVA-NP + M1 (G6) in adults aged ≥50 years (Fig. 3b). In
order to determine if the second vaccination with MVA-NP + M1 im-
proved the overall response (W0-W26), we compared the AUC be-
tween G5 and G6 (Supplementary Fig. 2). The combination of
Table 2
Vaccine safety and reactogenicity.
Severity of
AEs
Local arm
pain
Redness Swelling Warmth Itch Documented
fever
Feverishness Arthralgia Myalgia Fatigue Headache Nausea Malaise
ChAd prime
G1 and G2
Mild 13 4 11 3 0 3 2 3 8 8 10 4 4
Moderate 9 0 0 0 0 0 7 4 6 4 3 2 5
Severe 0 0 0 0 0 0 3 1 1 2 2 0 1
Any
severity
22 4 11 3 0 3 12 8 15 14 15 6 10
MVA prime
G3 and G4
Mild 11 3 10 6 0 0 7 4 7 12 10 7 13
Moderate 11 0 0 0 0 0 3 1 6 3 5 3 1
Severe 2 0 0 0 0 0 0 1 1 1 1 0 1
Any
severity
24 3 10 6 0 0 10 6 14 16 16 10 15
ChAd prime
G5 and G6 (≥50
years)
Mild 10 2 4 1 1 1 2 4 4 8 4 3 3
Moderate 2 0 0 0 1 1 3 3 3 2 9 0 0
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0
Any
severity
12 2 4 1 2 2 5 7 7 10 13 3 3
MVA boost at 8
weeks
G1
Mild 5 1 5 3 0 1 4 3 4 4 5 2 4
Moderate 5 0 1 0 0 0 3 1 1 2 2 1 4
Severe 2 0 1 0 0 0 0 2 2 1 0 0 0
Any
severity
12 1 7 3 0 1 7 6 7 7 7 3 8
MVA boost at 52
weeks
G2
Mild 6 2 5 3 0 0 5 3 6 6 6 1 6
Moderate 2 0 0 0 0 0 0 0 0 0 1 1 0
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0
Any
severity
8 2 5 3 0 0 5 3 6 6 7 2 6
ChAd boost at 8
weeks
G3
Mild 9 3 4 4 1 0 3 2 4 4 4 3 4
Moderate 1 0 0 0 0 1 2 0 0 1 3 0 1
Severe 0 0 0 0 0 0 0 0 0 0 0 1 0
Any
severity
10 3 4 4 1 1 5 2 4 5 7 4 5
ChAd boost at 52
weeks
G4
Mild 5 2 2 3 1 2 3 2 3 4 0 2 1
Moderate 3 0 0 1 0 1 0 3 4 3 0 0 3
Severe 1 0 0 0 0 0 2 0 0 0 0 0 0
Any
severity
9 2 2 4 1 3 5 5 7 7 0 2 4
MVA boost at 52
weeks
G6 (≥50 years)
Mild 3 0 1 1 0 0 0 1 2 3 1 1 2
Moderate 5 0 0 0 0 0 0 2 3 0 0 0 1
Severe 1 0 0 0 0 0 0 0 0 0 0 0 0
Any
severity
9 0 1 1 0 0 0 3 5 3 1 1 3
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vaccination with ChAdOx1 NP + M1 followed by MVA-NP + M1 had
higher AUC of immune response compared to ChAdOx1 NP + M1
alone (p= 0.04), although this difference was not signiﬁcant when an
outlier was excluded from Group 6 (p= 0.08). Responses to NP + M1
were increased N8-fold (median 1623 SFU/106 PBMC; p = 0.008) for
G5 and ~12-fold (median 1755 SFU/106 PBMC; p= 0.02) for G6 when
compared with baseline responses of 198 SFU/106 and 143 SFU/106 re-
spectively (Fig. 3b). Themean peak immune response after a single dose
of ChAdOx1NP+M1was higher in older adults (Groups 5+6:median
2036 SFU/106 PBMCs) compared to younger adults (Group 1 + 2: me-
dian 1147 SFU/106 PBMCs).
Importantly, 6 months after the ﬁrst vaccination, IFN-γ responses in
both groups were maintained at levels ~2.5-fold (G5) and 9-fold (G6)
higher than baseline.
3.5. Analysis of NP Speciﬁc IFN-γ ELISpot Responses
As a critical role for NP-speciﬁc T-cell responses in protection from
symptomatic inﬂuenza and reducing viral shedding has recently been
demonstrated (Hayward et al., 2015), we measured IFN-γ ELISpot re-
sponses speciﬁc for NP to determine if ChAdOx1 NP + M1 and MVA-
NP + M1 vaccination boosted these cross-reactive T-cell responses to
NP (Fig. 5a-d). In young adults (G1-G4), pre-existing baseline responses
to NP were boosted to signiﬁcantly higher levels following vaccination
and durably maintained at levels signiﬁcantly higher than baseline for
18 months after the ﬁrst vaccination, regardless of the vaccination reg-
imen employed (Fig. 5a, c). Responses to M1 antigen (253 amino acid
residues) were also signiﬁcantly boosted and maintained at levels sig-
niﬁcantly higher than baseline for 18 months after the ﬁrst vaccination
in all groups except G1.
In adults ≥ 50 years (G5 and G6), frequencies of NP orM1-speciﬁc T-
cells 8 weeks and 26 weeks after a single dose of ChAdOx1 NP + M1
were not signiﬁcantly higher than pre-vaccination levels (Fig. 5b, d).
However, the two dose (G6) vaccination regimen induced responses
to both NP and M1 at signiﬁcantly higher frequencies (NP: p =
0.0068; M1: p = 0.0136) than pre-vaccination levels up to 6 months
after ﬁrst vaccination.
We also measured the breadth of the IAV-speciﬁc T-cell response to
eight individual NP + M1 peptide pools by IFN-γ+ ELISpot (Supple-
mentary Fig. 3). We detected broad antigen-speciﬁc T-cell responses
across all peptide pools prior to vaccination (W0). Vaccination boosted
pre-existing responses to all peptide pools but did not increase the
breadth of the response by inducing responses to peptide pools in
which there was no prior response.
3.6. Phenotype of IAV-Speciﬁc IFN-γ+ CD8+ T-Cells
A subset of sampleswere analyzed byﬂowcytometry to characterize
the different T-cell memory subsets (Supplementary Table.1, Supple-
mentary Fig. 4, Supplementary Fig. 5, Supplementary Fig. 6). Popula-
tions of IFN-γ+ CD8+ T-cells were functionally phenotyped as naïve
cells (CD45RA+ CCR7+), effector memory T-cells (TEM; CD45RA
−
CCR7−), effectormemory RAT-cells (TEMRA; CD45RA
+ CCR7−) and cen-
tral memory T-cells (TCM; CD45RA
− CCR7+). In both young and older
adults, the majority of pre-existing memory IFN-γ+ CD8+ T-cells prior
to vaccinationwere either of the TCM or TEM phenotype (Supplementary
Fig. 6). In young adults, both ﬁrst and second vaccinations increased the
frequency of antigen-speciﬁc IFN-γ+ CD8+ TCM and TEM CD8
+ T-cells
for up to 18 months after the ﬁrst vaccination. In older adults, the in-
crease in antigen-speciﬁc IFN-γ+ CD8+ T-cells after vaccinationwas ob-
served only in the TCM pool.
4. Discussion
We have developed viral vectored inﬂuenza vaccines, MVA-NP
+ M1 and ChAdOx1 NP + M1, to provide broad spectrum protection
against inﬂuenza A virus by the boosting of pre-existing T-cell responses
to conserved inﬂuenza antigens. In this report we demonstrate that a
two-dose heterologous combination of these two viral vectored inﬂu-
enza vaccines is safe in young and older adults, signiﬁcantly increases
frequencies of cross-reactive T-cells and durably maintains these T-
cells at high frequencies for 18 months after vaccination.
We had previously demonstrated the safety of single dose vaccina-
tions with MVA-NP + M1 and ChAdOx1 NP + M1 vaccines in young
and older adults, identiﬁed an optimal dose balancing reactogenicity
and immunogenicity, and demonstrated the induction of inﬂuenza-spe-
ciﬁc T-cells following vaccination (Antrobus et al., 2014a; Antrobus et
al., 2014b; Antrobus et al., 2012; Berthoud et al., 2011; Lillie et al.,
2012). This study evaluated the combination of these two vaccines to
identify the optimal order and interval in the vaccination schedule.
We tested MVA-NP + M1 followed by ChAdOx1 NP + M1 (MVA/
ChAdOx1) and ChAdOx1 NP + M1 followed by MVA-NP + M1
(ChAdOx1/MVA) with an interval of either 8 weeks or 52 weeks be-
tween the two vaccines. Both vaccination combinations were well-tol-
erated in young and older adults with mild to moderate injection site
pain the most commonly reported adverse event. In young adults with
pre-existing inﬂuenza-speciﬁc T-cell responses, all four vaccination
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Fig. 3. Ex vivo IFN-γmedian ELISpot responses to inﬂuenza antigenNP+M1 involunteers
aged 18–46 and 50+ following vaccinationwith viral vectored vaccines. (a) G1-4:Median
ELISPOT Responses (NP + M1); (b) G5&6: Median ELISPOT Responses (NP + M1). (a)
Median IFN-γ ELISpot responses from vaccinated volunteers at baseline (W0) and at
intervals following ﬁrst (V1) and second vaccinations (V2) for Groups 1–4. Volunteers
were ﬁrst vaccinated intramuscularly (im) with ChAdOx1 NP + M1 (2.5 × 1010vp) and
subsequently vaccinated with MVA-NP + M1 (1.5 × 108 pfu) at week 8 (G1: W8) or
week 52 (G2: W52). Alternatively, volunteers were vaccinated im with MVA-NP + M1
(1.5 × 108 pfu) followed by vaccination with ChAdOx1 NP + M1 at W8 (G3) or W52
(G4). (b) Volunteers aged 50+ were vaccinated im with a single dose (G5) of ChAdOx1
NP + M1 (2.5 × 1010vp) or vaccinated with ChAdOx1 NP + M1 followed with MVA-NP
+ M1 (1·5 × 108 PFU) at W8 (G6). PBMC were stimulated with overlapping pools of
peptides corresponding to the NP + M1 vaccine antigen. Controls included cells
stimulated with PHA/SEB, PPD or irrelevant peptide TRAP33 (data not shown). Negative
control was cells stimulated with media alone (data not shown). Differences in
responses between selected time-points were determined using a two-tailed t-test
using Wilcoxon signed-rank test for matched pairs. *P b 0.05, **P b 0.01, ***P b 0.001, NS
= P N 0.05.
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regimes increased and maintained T-cell responses above pre-vaccina-
tion frequencies for 18 months. However, the MVA/ChAdOx1 regimen
with either an 8 week or 52 week interval maintained T-cell responses
at higher levels compared to the ChAdOx1/MVA regimen.
The long-term maintenance of T-cell responses is a critical compo-
nent of successful vaccination strategies as T-cell responses are thought
to be short lived following natural infection. A prospective study of T-
cell responses after a symptomatic infection found rapid decline in re-
sponses within a few months after infection (Hillaire et al., 2011)
while others have suggested that responses have a half-life of 2–
3 years (McMichael et al., 1983a).More recentwork has reported detec-
tion of T-cell responses many years after an infection, although it is un-
clear whether this was due to natural boosting in the intervening
period.(van de Sandt et al., 2015) More importantly, detectable T-cell
responses following natural infection are not necessarily present at pro-
tective levels. Although memory responses can still be boosted follow-
ing natural infection, cohort and challenge studies indicate that there
is a correlation between higher T-cell responses and reduction in symp-
tom severity, viral shedding and illness duration (Hayward et al., 2015;
McMichael et al., 1983b; Sridhar et al., 2013). This study shows that
after vaccination with viral vectors, T-cell responses are maintained at
high levels for a longperiod of time, raising the possibility that T cellme-
diated protection after vaccination could last for considerably longer
than T-cell mediated protection after natural infection. This report is
the longest follow-up of T-cell responses following inﬂuenza vaccina-
tion.Our studydemonstrates long-termmaintenance (up to18months)
of T-cell responses with a heterologous viral vector vaccine strategy.
Moreover, even a single dose of either viral vector vaccine in young
adults can maintain T-cells above pre-vaccination frequencies for up
to 1 year post-vaccination.
This long-term maintenance is critical in older adults in whom re-
ducing severity of illness is paramount, particularly as seasonal inﬂu-
enza vaccines have reduced efﬁcacy (McElhaney et al., 2016). In
contrast to young adults, a single dose of ChAdOx1 did not durably
maintain T-cell responses above pre-vaccination levels in older adults.
However, the two-dose heterologous combination schedule of
ChAdOx1/MVA boosted pre-existing T-cells and maintained these T-
cells at signiﬁcantly higher frequencies compared to pre-vaccination
levels up to 8 months after the ﬁrst vaccination. Longer follow-up of
these responses is warranted. It is notable that reactogenicity after the
ChAdOx1/MVA vaccination regimen was signiﬁcantly lower in older
adults compared to younger adults.
Our study showed no signiﬁcant difference in generation andmain-
tenance of immune responses between vaccination schedules with an
8 week or 52 week interval between doses. The two dose heterologous
regimen administered 1 year apart is of particular interest to integrate
into existing vaccination schedules and our data paves a development
pathway for viral vectored vaccines administered in conjunction with
existing strain-speciﬁc annual inﬂuenza vaccination. However, in older
adults a shorter interval is likely to be needed as T-cell responses decline
to pre-vaccination levels within 8weeks after a single dose of ChAdOx1.
In an outbreak scenario or pandemic setting, rapid induction of protec-
tive immune responses following vaccination is valuable to limit the se-
verity and spread of the outbreak.
Studies conducted during the evolution of the H1N1 pandemic in
2009 have demonstrated that cross-reactive T-cells can provide
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Fig. 4. Comparison of immune responses following 1st (V1) and 2nd (V2) vaccinationwith ChAd orMVA viral vectors. (a) G1-G2 vs G3-G4; (b) G1-G2 vsG3-G4; (c) G1-G4; (d) G1-G4. (a)
Comparison of fold changes in IFN-γ immunogenicity at the peak of the response following primary vaccination with either ChAdOx1 NP+M1 (G1&G2) or MVA-NP+M1 (G3&G4). (b)
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(G3&G4). The fold-increase in peak T-cell response over baseline following the ﬁrst (V1) MVA-NP + M1 vaccination was signiﬁcantly higher (~6-fold increase over baseline p= 0.048,
median = 251.7 SFU/106 PBMC) than that induced by ChAdOx1 NP + M1 (~4-fold increase over baseline, median = 265 SFU/106 PBMC). In comparing the fold-change in the peak of
the response following the second vaccination (V2), we observed responses induced by MVA-NP + M1 were ~2·3-fold greater (p= 0.02) than that induced by ChAdOx1 NP + M1.
(c) AUC analysis for each group in the 52 week interval was carried out to compare the effect of a second vaccination at W8 versus no V2 vaccination on overall immunogenicity. (d)
AUC analysis comparing overall immunogenicity for each group for the duration of the study (W0-W78). Abbreviations are as follows; AUC = area under the curve, ChAd = ChAdOx1
NP + M1 and MVA=MVA-NP +M1. Line represents the median. Differences between groups were calculated using an unpaired non-parametric test (Mann-Whitney). * = p b 0.05.
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protection against symptomatic pandemic inﬂuenza in the absence of
cross-protective antibodies. We show that both ChAdOx1 NP + M1
and MVA-NP + M1 rapidly boost pre-existing cross-reactive T-cells to
signiﬁcantly higher levels within 1–3weeks after vaccination. These re-
sponses remain above pre-existing frequencies up to 1 year post-vacci-
nation, although MVA-NP +M1 induces signiﬁcantly higher responses
than ChAdOx1 NP + M1. A single dose of MVA-NP + M1, potentially
stockpiled, is an attractive option for rapid development of T-cell immu-
nity in the event of a pandemic tomitigate the severity of the pandemic,
particularly in high-risk populations.
One limitation of this study is the lack of data on protective efﬁcacy.
However, in a previous experimental challenge study demonstrating re-
duced viral shedding and symptoms with a single dose of MVA-NP
+ M1, median IFN-γ ELISpot values of protected volunteers was 627
SFU/106 PBMC. In comparison, long-term IFN-γ ELISpot responses at
18 months and peak responses were higher than this value (at least
1.25-fold greater) for all two dose vaccination regimes. Based on these
data, we would speculate that a two-dose regimen is likely to confer
higher levels of protection in a challenge study or efﬁcacy trial. Further
work is necessary to determine efﬁcacy of these vaccines and the dura-
bility of protection. A key question in the potential deployment of our
broadly protective T-cell vaccines is their use with existing inactivated
and live vaccines, particularly in the elderly. Our study does not address
this issue although further work is underway to assess strategies com-
bining these viral vector vaccines with existing inﬂuenza vaccines
(NCT03300362).
In conclusion, we have demonstrated that vaccines which stimulate
T-cell responses against conserved antigens generate robust and dura-
ble immune responses that could confer broad and potentially long-
lasting protection against inﬂuenza virus. This has the potential to pro-
foundly impact both seasonal andpandemic inﬂuenza vaccination strat-
egies, especially in high risk groups such as older adults.
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Table 1. Trial study design and participant demographics. G1 and G2
were ﬁrst vaccinated with ChAdOx1 NP + M1 followed by a second
MVA-NP + M1 vaccination 8 weeks later (W8; G1) or 52 weeks later
(W52; G2). Volunteers in G3 and G4 received their ﬁrst vaccination
with MVA-NP + M1 followed by a second vaccination with ChAdOx1
NP + M1 at W8 or W52. G5 received ChAdOx1 NP + M1 alone and
G6 received ChAdOx1 NP + M1 followed by an additional vaccination
with MVA-NP +M1 at W8.
Table 2. Vaccine safety and reactogenicity. The number of volunteers
experiencing local and systemic AEs after each vaccination. Only AEs
with possible, probable or deﬁnite causal relationships are shown. The
most common local AE was mild injection site pain and the most com-
mon systemic AE was mild fatigue and headache.
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